{"id":62811,"date":"2026-04-10T23:21:23","date_gmt":"2026-04-10T15:21:23","guid":{"rendered":"https:\/\/flcube.com\/?p=62811"},"modified":"2026-04-10T23:21:25","modified_gmt":"2026-04-10T15:21:25","slug":"shanghai-ark-bio-advances-ak0406-a-next-gen-long-acting-influenza-adfc-into-phase-i-trial-in-australia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62811","title":{"rendered":"Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia"},"content":{"rendered":"\n<p><strong>Shanghai Ark Biopharmaceutical Co., Ltd.<\/strong>, a China-based clinical-stage biotech, announced that its investigational long-acting antiviral candidate <strong>AK0406<\/strong> has received ethics clearance from the <strong>Australian Human Research Ethics Committee (HREC)<\/strong> and has <strong>dosed its first cohort of healthy adult volunteers<\/strong> in a Phase I clinical trial. AK0406 is a novel <strong>antiviral drug\u2013Fc conjugate (ADFC)<\/strong> engineered for <strong>broad-spectrum, potent, and extended-duration activity<\/strong> against influenza viruses.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-snapshot\">Development Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Candidate<\/strong><\/td><td>AK0406<\/td><\/tr><tr><td><strong>Class<\/strong><\/td><td>Antiviral Drug\u2013Fc Conjugate (ADFC)<\/td><\/tr><tr><td><strong>Target Indication<\/strong><\/td><td>Influenza (prophylaxis and treatment)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase I (first-in-human)<\/td><\/tr><tr><td><strong>Location<\/strong><\/td><td>Australia (HREC-approved sites)<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>First cohort dosed; safety and PK monitoring underway<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>Structural and pharmacokinetic optimization over first-gen ADFCs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-amp-preclinical-differentiation\">Mechanism &amp; Preclinical Differentiation<\/h2>\n\n\n\n<p>AK0406 fuses a proprietary <strong>small-molecule antiviral agent<\/strong> to the <strong>Fc domain of a human antibody<\/strong>, leveraging FcRn-mediated recycling to extend half-life while maintaining high viral neutralization potency. Key advantages over earlier ADFC platforms include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Broad-spectrum activity<\/strong> against influenza A and B strains, including oseltamivir-resistant variants<\/li>\n\n\n\n<li><strong>Sustained plasma exposure<\/strong> enabling once-weekly or less frequent dosing<\/li>\n\n\n\n<li><strong>Enhanced manufacturability<\/strong> via streamlined conjugation chemistry<\/li>\n\n\n\n<li><strong>Improved in vitro and in vivo potency<\/strong> (sub-nanomolar EC\u2085\u2080 in multiple models)<\/li>\n<\/ul>\n\n\n\n<p>Preclinical studies demonstrated <strong>viral load reductions of &gt;99%<\/strong> in murine challenge models with a single dose, supporting potential use in both seasonal and pandemic settings.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-for-australian-trial\">Strategic Rationale for Australian Trial<\/h2>\n\n\n\n<p>Conducting early-phase trials in Australia offers <strong>accelerated regulatory timelines<\/strong>, experienced clinical sites for antiviral studies, and a favorable environment for global data recognition. Positive results could support parallel filings with the <strong>U.S. FDA<\/strong> and <strong>China NMPA<\/strong> under expedited pathways for pandemic preparedness countermeasures.<\/p>\n\n\n\n<p>Ark Bio\u2019s ADFC platform represents a <strong>next-generation evolution<\/strong> beyond neuraminidase inhibitors and monoclonal antibodies, combining small-molecule efficacy with biologic-like durability.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-amp-public-health-implications\">Market &amp; Public Health Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> Current antivirals require daily dosing and face rising resistance; no long-acting injectable option exists for influenza<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Prophylactic use in high-risk populations (elderly, immunocompromised) and pandemic stockpiling scenarios<\/li>\n\n\n\n<li><strong>Platform Applicability:<\/strong> ADFC technology may be adapted to other respiratory viruses (e.g., RSV, coronaviruses)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory strategy, and platform potential. Actual outcomes are subject to trial results, regulatory decisions, and competitive developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Ark Biopharmaceutical Co., Ltd., a China-based clinical-stage biotech, announced that its investigational long-acting antiviral&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1443,62],"class_list":["post-62811","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-ark-biopharmaceutical","tag-clinical-trial-approval-initiation"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Ark Biopharmaceutical Co., Ltd., a China-based clinical-stage biotech, announced that its investigational long-acting antiviral candidate AK0406 has received ethics clearance from the Australian Human Research Ethics Committee (HREC) and has dosed its first cohort of healthy adult volunteers in a Phase I clinical trial. AK0406 is a novel antiviral drug\u2013Fc conjugate (ADFC) engineered for broad-spectrum, potent, and extended-duration activity against influenza viruses.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62811\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia\" \/>\n<meta property=\"og:description\" content=\"Shanghai Ark Biopharmaceutical Co., Ltd., a China-based clinical-stage biotech, announced that its investigational long-acting antiviral candidate AK0406 has received ethics clearance from the Australian Human Research Ethics Committee (HREC) and has dosed its first cohort of healthy adult volunteers in a Phase I clinical trial. AK0406 is a novel antiviral drug\u2013Fc conjugate (ADFC) engineered for broad-spectrum, potent, and extended-duration activity against influenza viruses.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62811\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-10T15:21:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-10T15:21:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62811#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62811\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia\",\"datePublished\":\"2026-04-10T15:21:23+00:00\",\"dateModified\":\"2026-04-10T15:21:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62811\"},\"wordCount\":378,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ark Biopharmaceutical\",\"Clinical trial approval \\\/ initiation\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62811#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62811\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62811\",\"name\":\"Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-10T15:21:23+00:00\",\"dateModified\":\"2026-04-10T15:21:25+00:00\",\"description\":\"Shanghai Ark Biopharmaceutical Co., Ltd., a China-based clinical-stage biotech, announced that its investigational long-acting antiviral candidate AK0406 has received ethics clearance from the Australian Human Research Ethics Committee (HREC) and has dosed its first cohort of healthy adult volunteers in a Phase I clinical trial. AK0406 is a novel antiviral drug\u2013Fc conjugate (ADFC) engineered for broad-spectrum, potent, and extended-duration activity against influenza viruses.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62811#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62811\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62811#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Ark Biopharmaceutical Co., Ltd., a China-based clinical-stage biotech, announced that its investigational long-acting antiviral candidate AK0406 has received ethics clearance from the Australian Human Research Ethics Committee (HREC) and has dosed its first cohort of healthy adult volunteers in a Phase I clinical trial. AK0406 is a novel antiviral drug\u2013Fc conjugate (ADFC) engineered for broad-spectrum, potent, and extended-duration activity against influenza viruses.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62811","og_locale":"en_US","og_type":"article","og_title":"Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia","og_description":"Shanghai Ark Biopharmaceutical Co., Ltd., a China-based clinical-stage biotech, announced that its investigational long-acting antiviral candidate AK0406 has received ethics clearance from the Australian Human Research Ethics Committee (HREC) and has dosed its first cohort of healthy adult volunteers in a Phase I clinical trial. AK0406 is a novel antiviral drug\u2013Fc conjugate (ADFC) engineered for broad-spectrum, potent, and extended-duration activity against influenza viruses.","og_url":"https:\/\/flcube.com\/?p=62811","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-10T15:21:23+00:00","article_modified_time":"2026-04-10T15:21:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62811#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62811"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia","datePublished":"2026-04-10T15:21:23+00:00","dateModified":"2026-04-10T15:21:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62811"},"wordCount":378,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ark Biopharmaceutical","Clinical trial approval \/ initiation"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62811#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62811","url":"https:\/\/flcube.com\/?p=62811","name":"Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-10T15:21:23+00:00","dateModified":"2026-04-10T15:21:25+00:00","description":"Shanghai Ark Biopharmaceutical Co., Ltd., a China-based clinical-stage biotech, announced that its investigational long-acting antiviral candidate AK0406 has received ethics clearance from the Australian Human Research Ethics Committee (HREC) and has dosed its first cohort of healthy adult volunteers in a Phase I clinical trial. AK0406 is a novel antiviral drug\u2013Fc conjugate (ADFC) engineered for broad-spectrum, potent, and extended-duration activity against influenza viruses.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62811#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62811"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62811#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62811"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62811\/revisions"}],"predecessor-version":[{"id":62813,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62811\/revisions\/62813"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}